Novavax Inc. (NASDAQ:NVAX) reported first-quarter 2025 sales of $667 million, compared to $94 million a year ago, beating the ...

Novavax (NASDAQ:NVAX) pivots back to profitability after delivering a $666.7 million revenue haul in Q1surpassing estimates ...

Novavax (NASDAQ:NVAX) shares climbed ~35% in the premarket on Thursday after the COVID-19 vaccine maker lifted its full-year ...

Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

QBTS: D-Wave Quantum shares are rallying after the company beat analysts' estimates and reported record quarterly revenue ...

The company raised its full-year revenue guidance to between $975 million and $1.025 billion, up from its previous guidance ...

Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ETCompany ParticipantsLuis Sanay - Vice President, Investor ...

On a per-share basis, the Gaithersburg, Maryland-based company said it had net income of $2.93. The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...

Analysts are estimating that Novavax will report an earnings per share (EPS) of $0.19. The market awaits Novavax's ...

Novavax Inc. closed 73.72% short of its 52-week high of $23.86, which the company achieved on June 6th.

A new randomized study could cost Novavax tens of millions of dollars, vaccine experts say ...